Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Cooper ZD"'
Autor:
Cooper, ZD, Johnson, KW, Pavlicova, M, Glass, A, Vosburg, SK, Sullivan, MA, Manubay, J, Martinez, D, Jones, JD, Saccone, PA, Comer, SD
Glial activation is hypothesized to contribute directly to opioid withdrawal. This study investigated the dose-dependent effects of a glial cell modulator, ibudilast, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ee47db3266df06437a76afece16f0774
https://europepmc.org/articles/PMC4644513/
https://europepmc.org/articles/PMC4644513/
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Addiction; Apr2010, Vol. 105 Issue 4, p709-718, 10p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alayoubi M; UCLA, Neuroscience Interdepartmental Graduate Program, University of California, Los Angeles, USA.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA.; Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, USA., Henry BA; UCLA, Neuroscience Interdepartmental Graduate Program, University of California, Los Angeles, USA.; Department of Psychiatry and Biobehavioral Science, UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, 760 Westwood Plaza, 37-418, Los Angeles, CA, 90095, USA., Cahill CM; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA.; Shirley and Stefan Hatos Center for Neuropharmacology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, USA., Cooper ZD; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, USA. zcooper@mednet.ucla.edu.; Department of Psychiatry and Biobehavioral Science, UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, 760 Westwood Plaza, 37-418, Los Angeles, CA, 90095, USA. zcooper@mednet.ucla.edu.; Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA. zcooper@mednet.ucla.edu.
Publikováno v:
Drugs [Drugs] 2024 Oct 10. Date of Electronic Publication: 2024 Oct 10.
Autor:
Sanchez JI; Department of Medicine, Division of Cardiology, and Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Fong RS; Department of Medicine, Division of Cardiology, and Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Hampilos K; Department of Medicine, Division of Cardiology, and Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Cooper ZD; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, and Department of Anesthesiology and Perioperative Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Middlekauff HR; Department of Medicine, Division of Cardiology, and Department of Physiology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA. Hmiddlekauff@mednet.ucla.edu.
Publikováno v:
Journal of general internal medicine [J Gen Intern Med] 2024 Sep 23. Date of Electronic Publication: 2024 Sep 23.
Autor:
McManus KR; Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095 USA., Venegas A; Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095 USA., Cooper ZD; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095, USA; Department of Anesthesiology and Perioperative Medicine, University of California, Los Angeles, CA 90095, USA., Ray LA; Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095 USA; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095, USA; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: lararay@psych.ucla.edu.
Publikováno v:
Addictive behaviors [Addict Behav] 2025 Jan; Vol. 160, pp. 108189. Date of Electronic Publication: 2024 Oct 09.
Autor:
Amir CM; Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.; Neuroscience Interdepartmental Program, University of California, Los Angeles, CA, USA., Ghahremani DG; Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.; Center for Cannabis and Cannabinoids, University of California, Los Angeles., Chang SE; Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.; Neuroscience Interdepartmental Program, University of California, Los Angeles, CA, USA., Cooper ZD; Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.; Center for Cannabis and Cannabinoids, University of California, Los Angeles., Bearden CE; Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.; Department of Psychology, University of California, Los Angeles, CA, USA.
Publikováno v:
MedRxiv : the preprint server for health sciences [medRxiv] 2024 Aug 23. Date of Electronic Publication: 2024 Aug 23.
Autor:
Murray CH; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.) conormurray@mednet.ucla.edu., Gannon BM; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.)., Winsauer PJ; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.)., Cooper ZD; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.)., Delatte MS; UCLA Center for Cannabis and Cannabinoids, Jane and Terry Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Biobehavioral Sciences (C.H.M.) and Departments of Anesthesiology and Perioperative Medicine (Z.D.C.), David Geffen School of Medicine, University of California, Los Angeles, California; Department of Pharmacology and Toxicology, College of Medicine (B.M.G.) and Office of Research Regulatory Affairs, Division of Research and Innovation (B.M.G.), University of Arkansas for Medical Sciences, Little Rock, Arkansas; Departments of Pharmacology and Experimental Therapeutics and Biochemistry and Molecular Biology, School of Medicine (P.J.W.), and Alcohol and Drug Abuse Center of Excellence (P.J.W.) Louisiana State University Health Sciences Center, New Orleans, Louisiana; and Regulatory and Drug Development Consulting, Allucent, Carey, North Carolina (M.S.D.).
Publikováno v:
Pharmacological reviews [Pharmacol Rev] 2024 Aug 15; Vol. 76 (5), pp. 915-955. Date of Electronic Publication: 2024 Aug 15.